Cargando…

Proteasome Activator Enhances Survival of Huntington's Disease Neuronal Model Cells

In patients with Huntington's disease (HD), the proteolytic activity of the ubiquitin proteasome system (UPS) is reduced in the brain and other tissues. The pathological hallmark of HD is the intraneuronal nuclear protein aggregates of mutant huntingtin. We determined how to enhance UPS functio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Hyemyung, Sonntag, Kai-Christian, Kim, Woori, Cattaneo, Elena, Isacson, Ole
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1800909/ https://www.ncbi.nlm.nih.gov/pubmed/17327906 http://dx.doi.org/10.1371/journal.pone.0000238

Ejemplares similares

Age-associated chromatin relaxation is enhanced in Huntington's disease mice
por: Park, Myungsun, et al.
Publicado: (2017)

The Ubiquitin-Proteasome Pathway in Huntington's Disease
por: Mitra, Siddhartha, et al.
Publicado: (2008)

Ubiquitin–proteasome system involvement in Huntington’s disease
por: Ortega, Zaira, et al.
Publicado: (2014)

Indirect inhibition of 26S proteasome activity in a cellular model of Huntington’s disease
por: Hipp, Mark S., et al.
Publicado: (2012)

The Ubiquitin-Proteasome System in Huntington's Disease: Are Proteasomes Impaired, Initiators of Disease, or Coming to the Rescue?
por: Schipper-Krom, Sabine, et al.
Publicado: (2012)

The Ubiquitin-Proteasome Reporter GFPu Does Not Accumulate in Neurons of the R6/2 Transgenic Mouse Model of Huntington's Disease
por: Bett, John S., et al.
Publicado: (2009)

The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias
por: Davies, Janet E, et al.
Publicado: (2007)

Impaired ubiquitin–proteasome system activity in the synapses of Huntington's disease mice
por: Wang, Jianjun, et al.
Publicado: (2008)

Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington’s Disease
por: Dasgupta, Sayani, et al.
Publicado: (2015)

Modulation of SETDB1 activity by APQ ameliorates heterochromatin condensation, motor function, and neuropathology in a Huntington’s disease mouse model
por: Hwang, Yu Jin, et al.
Publicado: (2021)

Pitfalls in the detection of cholesterol in Huntington’s disease models
por: Marullo, Manuela, et al.
Publicado: (2012)

The proteasome regulator PI31 is required for protein homeostasis, synapse maintenance, and neuronal survival in mice
por: Minis, Adi, et al.
Publicado: (2019)

VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington’s disease
por: Díaz-Alonso, Javier, et al.
Publicado: (2016)

Modelling Proteasome and Proteasome Regulator Activities
por: Liepe, Juliane, et al.
Publicado: (2014)

Survival of Korean Huntington’s Disease Patients
por: Kim, Han-Joon, et al.
Publicado: (2016)

Brain cells derived from Alzheimer’s disease patients have multiple specific innate abnormalities in energy metabolism
por: Ryu, Woo-In, et al.
Publicado: (2021)

Transcriptional vulnerabilities of striatal neurons in human and rodent models of Huntington’s disease
por: Matsushima, Ayano, et al.
Publicado: (2023)

Fullerenols Prevent Neuron Death and Reduce Oxidative Stress in Drosophila Huntington’s Disease Model
por: Bolshakova, Olga I., et al.
Publicado: (2022)

Longevity-Associated Variant of BPIFB4 Confers Neuroprotection in the STHdh Cell Model of Huntington Disease
por: Cattaneo, Monica, et al.
Publicado: (2022)

Enhancement of BACE1 Activity by p25/Cdk5-Mediated Phosphorylation in Alzheimer’s Disease
por: Song, Woo-Joo, et al.
Publicado: (2015)

Cellular prion protein promotes post-ischemic neuronal survival, angioneurogenesis and enhances neural progenitor cell homing via proteasome inhibition
por: Doeppner, T R, et al.
Publicado: (2015)

AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington's disease
por: Vázquez-Manrique, Rafael P., et al.
Publicado: (2016)

H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth
por: Lee, Min Jae, et al.
Publicado: (2019)

Mechanisms That Activate 26S Proteasomes and Enhance Protein Degradation
por: Goldberg, Alfred L., et al.
Publicado: (2021)

Iron Accumulates in Huntington’s Disease Neurons: Protection by Deferoxamine
por: Chen, Jianfang, et al.
Publicado: (2013)

The mechanism of degeneration of striatal neuronal subtypes in Huntington disease
por: Rikani, Azadeh A., et al.
Publicado: (2014)

The Ubiquitin Proteasome System Is a Key Regulator of Pluripotent Stem Cell Survival and Motor Neuron Differentiation
por: Bax, Monique, et al.
Publicado: (2019)

Neuronal Activity in the Hibernating Brain
por: Sonntag, Mandy, et al.
Publicado: (2019)

New label-free methods for protein relative quantification applied to the investigation of an animal model of Huntington Disease
por: Cozzolino, Flora, et al.
Publicado: (2020)

A novel specific PERK activator reduces toxicity and extends survival in Huntington's disease models
por: Ganz, Javier, et al.
Publicado: (2020)

Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease
por: Koprich, James B, et al.
Publicado: (2008)

The Proteasome Activators Blm10/PA200 Enhance the Proteasomal Degradation of N-Terminal Huntingtin
por: Aladdin, Azzam, et al.
Publicado: (2020)

Decreased BDNF Release in Cortical Neurons of a Knock-in Mouse Model of Huntington’s Disease
por: Yu, Chenglong, et al.
Publicado: (2018)

Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of Huntington’s disease
por: Wu, Zheng, et al.
Publicado: (2020)

Liraglutide Improves Cognitive and Neuronal Function in 3-NP Rat Model of Huntington’s Disease
por: Shawki, Samar M., et al.
Publicado: (2021)

Dysregulated Neuronal Activity Patterns Implicate Corticostriatal Circuit Dysfunction in Multiple Rodent Models of Huntington's Disease
por: Miller, Benjamin R., et al.
Publicado: (2011)

Correction: Iron Accumulates in Huntington’s Disease Neurons: Protection by Deferoxamine
por: Chen, Jianfang, et al.
Publicado: (2013)

Striatal parvalbuminergic neurons are lost in Huntington's disease: implications for dystonia
por: Reiner, Anton, et al.
Publicado: (2013)

Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease
por: Velusamy, Thirunavukkarasu, et al.
Publicado: (2017)

Deficits in coordinated neuronal activity and network topology are striatal hallmarks in Huntington’s disease
por: Fernández-García, S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d6dejj9athgdpk8jbcc830shvd